Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer

MC0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•Biopsy proven primary colorectal adenocarcinoma or suspected pancreatic ductal adenocarcinoma, as agreed on by multidisciplinary team;
•No prior chemo(radio)therapy in rectal cancer patients.
•Patient scheduled to undergo surgery;
•Patients treated in the LUMC.
•Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations

•Contraindication for PET (pregnancy, breast-feeding and severe claustrophobia);
•Impaired renal function (creatinine clearance < 60 mL/min according to the CockcroftGault equation or ureum < 2x ULN (Upper limit of normal);
•Impaired liver function (ALAT, ASAT > 3 ULN or total bilirubin >2x ULN);
•Known allergy to pABA (p-aminobenzoate sodium salt);
•Presence of any psychological, familial, sociological or geographical conditionpotentially hampering compliance with the study protocol and follow-up schedule;
•Inability to tolerate lying supine for the duration of a PET/CT examination (~30min).

发起方